BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. JCO 2009;27:605-11. [DOI: 10.1200/jco.2008.18.0182] [Cited by in Crossref: 458] [Cited by in F6Publishing: 175] [Article Influence: 38.2] [Reference Citation Analysis]
Number Citing Articles
1 Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011;31:403-404. [PMID: 19830433 DOI: 10.1007/s00296-009-1202-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
2 Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014;14:31. [PMID: 24533834 DOI: 10.1186/1471-230X-14-31] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
3 Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015; 7(3): 344-361 [PMID: 25848463 DOI: 10.4254/wjh.v7.i3.344] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
4 Chen MH, Wu CS, Chen MH, Tsai CY, Lee FY, Huang YH. High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. Int J Mol Sci 2021;22:9116. [PMID: 34502025 DOI: 10.3390/ijms22179116] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lee HL, Jang JW, Han JW, Lee SW, Bae SH, Choi JY, Han NI, Yoon SK, Kim HJ, Lee S, Cho SG, Min CK, Kim DW, Lee JW. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B. Dig Dis Sci 2019;64:2992-3000. [PMID: 30982209 DOI: 10.1007/s10620-019-05614-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Charpin C, Guis S, Colson P, Borentain P, Mattéi JP, Alcaraz P, Balandraud N, Thomachot B, Roudier J, Gérolami R. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:R179. [PMID: 19941642 DOI: 10.1186/ar2868] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
7 Dyson JK, Hudson M, McPherson S. Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. Clin Med (Lond). 2014;14:551-555. [PMID: 25301924 DOI: 10.7861/clinmedicine.14-5-551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
8 Kotake T, Satake H, Okita Y, Hatachi Y, Hamada M, Omiya M, Yasui H, Hashida T, Kaihara S, Inokuma T, Tsuji A. Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection. Asia Pac J Clin Oncol. 2019;15:63-68. [PMID: 29984542 DOI: 10.1111/ajco.13050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283x1245024510.1177_1756283x12450245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Yazdany J, Calabrese L. Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines? Arthritis Care Res (Hoboken) 2010;62:585-9. [PMID: 20191573 DOI: 10.1002/acr.20167] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
11 Li Z, Dong Y, Fan M, Yin Y, Zhu J, Li B, Huang W. Analysis of Hepatitis B Virus Reactivation After Radiotherapy in Patients With Hepatocellular Carcinoma Using the Lyman NTCP Model. Technol Cancer Res Treat 2019;18:1533033819875136. [PMID: 31526114 DOI: 10.1177/1533033819875136] [Reference Citation Analysis]
12 Nishida T, Matsubara T, Yakushijin T, Inada M. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. Hepatol Int 2019;13:407-15. [PMID: 31290069 DOI: 10.1007/s12072-019-09966-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci 2021;112:1943-54. [PMID: 33576088 DOI: 10.1111/cas.14846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Tsai YF, Yang CI, Du JS, Lin MH, Tang SH, Wang HC, Cho SF, Liu YC, Su YC, Dai CY, Hsiao HH. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study. PeerJ 2019;7:e7481. [PMID: 31565551 DOI: 10.7717/peerj.7481] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
15 Sagnelli E, Pisaturo M, Sagnelli C, Coppola N. Rituximab-based treatment, HCV replication, and hepatic flares. Clin Dev Immunol. 2012;2012:945950. [PMID: 22919406 DOI: 10.1155/2012/945950] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
16 Muraishi J, Shibata M, Honma Y, Hiura M, Abe S, Harada M. Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma. Intern Med 2017;56:1967-71. [PMID: 28768965 DOI: 10.2169/internalmedicine.56.8233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
17 Jang JW, Kim YW, Lee SW, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK, Chung KW. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. PLoS One. 2015;10:e0122041. [PMID: 25894607 DOI: 10.1371/journal.pone.0122041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
18 Kalinka E, Drozd-Sokołowska J, Waszczuk-Gajda A, Barankiewicz J, Zalewska E, Symonowicz I, Lech-Marańda E. Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland - a report of the Polish Lymphoma Research Group. Arch Med Sci 2020;16:157-61. [PMID: 32051719 DOI: 10.5114/aoms.2019.86761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tang Z, Li X, Wu S, Liu Y, Qiao Y, Xu D, Li J. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis. Hepatol Int. 2017;11:429-433. [PMID: 28856548 DOI: 10.1007/s12072-017-9817-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
20 Yamauchi R, Takeyama Y, Takata K, Fukunaga A, Sakurai K, Tanaka T, Fukuda H, Fukuda S, Kunimoto H, Umeda K, Morihara D, Yokoyama K, Irie M, Shakado S, Sakisaka S, Hirai F. Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate. Intern Med 2020;59:1163-6. [PMID: 31956202 DOI: 10.2169/internalmedicine.3805-19] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9(25): 1043-1053 [PMID: 28951776 DOI: 10.4254/wjh.v9.i25.1043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
22 Felis-Giemza A, Olesińska M, Świerkocka K, Więsik-Szewczyk E, Haładyj E. Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatol Int 2015;35:385-92. [PMID: 25549599 DOI: 10.1007/s00296-014-3195-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wang J, Jia J, Chen R, Ding S, Xu Q, Zhang T, Chen X, Liu S, Lu F. RFX1 participates in doxorubicin-induced hepatitis B virus reactivation. Cancer Med 2018;7:2021-33. [PMID: 29601674 DOI: 10.1002/cam4.1468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
24 黄利华, 姚悦萍. HBV感染者化疗时的抗病毒治疗. 世界华人消化杂志 2011; 19(15): 1604-1608 [DOI: 10.11569/wcjd.v19.i15.1604] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Yilmaz B, Erdem D, Teker F, Goren I, Yildirim B, Kut E, Sarikaya D, Atay MH, Yucel I. The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumours. J Int Med Res 2016;44:627-38. [PMID: 27048386 DOI: 10.1177/0300060516638992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
26 Ali K, Sial AA, Baig MT, Baig N, Ansari SH, Shamsi TS. Detection of the Incidence of HBV, HCV Infection and Febrile Neutropenia Associated With CHOP With or Without Rituximab in Diffuse Large B-Cell Lymphoma-Treated Patients. Hosp Pharm 2018;53:194-7. [PMID: 30147140 DOI: 10.1177/0018578717741394] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Cheung KS, Seto WK, Lai CL, Yuen MF. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatol Int. 2016;10:407-414. [PMID: 26739135 DOI: 10.1007/s12072-015-9692-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
28 Midorikawa Y, Takayama T, Nakayama H, Higaki T, Moriguchi M, Moriya K, Kanda T, Matsuoka S, Moriyama M. Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma. BMC Gastroenterol 2019;19:147. [PMID: 31426746 DOI: 10.1186/s12876-019-1069-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? Int J Infect Dis. 2011;15:e2-16. [PMID: 21074471 DOI: 10.1016/j.ijid.2010.03.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 108] [Article Influence: 11.9] [Reference Citation Analysis]
30 Wu Y, Huang H, Luo Y. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:610500. [PMID: 33613534 DOI: 10.3389/fimmu.2020.610500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Huang W, Zhang W, Fan M, Lu Y, Zhang J, Li H, Li B. Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma. Cancer Sci. 2014;105:697-703. [PMID: 24654677 DOI: 10.1111/cas.12400] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
32 Bright PD, Smith L, Usher J, Donati M, Johnston SL, Gompels MM, Unsworth DJ. False interpretation of diagnostic serology tests for patients treated with pooled human immunoglobulin G infusions: a trap for the unwary. Clin Med (Lond) 2015;15:125-9. [PMID: 25824062 DOI: 10.7861/clinmedicine.15-2-125] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
33 Lee SF, Evens AM, Ng AK, Luque-Fernandez MA. Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study. Sci Rep 2021;11:17950. [PMID: 34504223 DOI: 10.1038/s41598-021-97455-5] [Reference Citation Analysis]
34 Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol 2015; 7(7): 954-967 [PMID: 25954478 DOI: 10.4254/wjh.v7.i7.954] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
35 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immuno–suppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6i6.384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-1125/1/142] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Yoshida T, Kusumoto S, Inagaki A, Mori F, Ito A, Ri M, Ishida T, Komatsu H, Iida S, Sugauchi F. Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports. Int J Hematol. 2010;91:844-849. [PMID: 20473594 DOI: 10.1007/s12185-010-0592-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
38 Bertoletti A, Le Bert N. Immunotherapy for Chronic Hepatitis B Virus Infection. Gut Liver 2018;12:497-507. [PMID: 29316747 DOI: 10.5009/gnl17233] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 19.5] [Reference Citation Analysis]
39 Paul S, Dickstein A, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. Hepatology. 2017;66:379-388. [PMID: 28128861 DOI: 10.1002/hep.29082] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 20.8] [Reference Citation Analysis]
40 Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine (Baltimore). 2016;95:e4311. [PMID: 27472708 DOI: 10.1097/md.0000000000004311] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
41 Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170-1180. [PMID: 21115603 DOI: 10.1093/annonc/mdq583] [Cited by in Crossref: 213] [Cited by in F6Publishing: 192] [Article Influence: 19.4] [Reference Citation Analysis]
42 Lai CL, Yuen MF. Management of chronic hepatitis B in patients from special populations. Cold Spring Harb Perspect Med. 2015;5:pii a021527. [PMID: 26033083 DOI: 10.1101/cshperspect.a021527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
43 Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: Updates in 2013. World J Gastroenterol 2014; 20(40): 14581-14588 [PMID: 25356022 DOI: 10.3748/wjg.v20.i40.14581] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
44 Yang F, Zhu HL, He C, Li JJ, Xiang B, Cui X, Huang J, Ji J, Ma HB, Liu T. Effect of Antiviral Prophylaxis Strategy for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients with Hepatitis B Virus Infection: A Retrospective Cohort Study. Indian J Hematol Blood Transfus 2014;30:97-104. [PMID: 24839363 DOI: 10.1007/s12288-012-0195-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
45 Seetharam A, Perrillo R, Gish R. Immunosuppression in Patients with Chronic Hepatitis B. Curr Hepatol Rep. 2014;13:235-244. [PMID: 25101233 DOI: 10.1007/s11901-014-0238-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
46 Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010;116:4532-41. [PMID: 20702778 DOI: 10.1182/blood-2010-05-283309] [Cited by in Crossref: 173] [Cited by in F6Publishing: 167] [Article Influence: 15.7] [Reference Citation Analysis]
47 Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X, Zhao M, Zhang B, Jiang W, Lin Z, Ma Y, Yang Y, Huang Y, Zhao H, Xu R, Hong S, Zhang L. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer 2019;7:322. [PMID: 31753012 DOI: 10.1186/s40425-019-0808-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 20.5] [Reference Citation Analysis]
48 Wong GL, Wong VW, Chan HL. Virus and Host Testing to Manage Chronic Hepatitis B. Clin Infect Dis 2016;62 Suppl 4:S298-305. [PMID: 27190319 DOI: 10.1093/cid/ciw024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
49 Aguiar-Bujanda D, Blanco-Sánchez MJ, Hernández-Sosa M, Galván-Ruíz S, Hernández-Sarmiento S. Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. Cancer Manag Res 2015;7:319-30. [PMID: 26604821 DOI: 10.2147/CMAR.S69145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M, Kimura S. Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia. Int J Hematol. 2015;102:379-382. [PMID: 25842192 DOI: 10.1007/s12185-015-1788-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
51 Marzano A. Management of HBV infection during immunosuppressive treatment. Mediterr J Hematol Infect Dis. 2009;1:e2009025. [PMID: 21415959 DOI: 10.4084/mjhid.2009.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
52 Tavakolpour S, Alavian SM, Sali S. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened. Hepat Mon 2016;16:e35810. [PMID: 27257429 DOI: 10.5812/hepatmon.35810] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
53 韦花媚, 罗春英. 乙型肝炎病毒和淋巴瘤关系的研究进展. 世界华人消化杂志 2014; 22(27): 4081-4086 [DOI: 10.11569/wcjd.v22.i27.4081] [Reference Citation Analysis]
54 Samal J, Kandpal M, Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012;25:142-163. [PMID: 22232374 DOI: 10.1128/cmr.00018-11] [Cited by in Crossref: 91] [Cited by in F6Publishing: 58] [Article Influence: 10.1] [Reference Citation Analysis]
55 Visram A, Chan KK, McGee P, Boro J, Hicks LK, Feld JJ. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS One. 2015;10:e0120749. [PMID: 25875198 DOI: 10.1371/journal.pone.0120749] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
56 Park H, Kim DY, Kim SJ, Chung H, Cho H, Jang JE, Cheong JW, Min YH, Song JW, Kim JS. HBsAg-Negative, Anti-HBc-Negative Patients Still Have a Risk of Hepatitis B Virus-Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma. Cancer Res Treat 2018;50:1121-9. [PMID: 29198097 DOI: 10.4143/crt.2017.329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Hwang JP, Fisch MJ, Zhang H, Kallen MA, Routbort MJ, Lal LS, Vierling JM, Suarez-Almazor ME. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012;8:e32-e39. [PMID: 23180996 DOI: 10.1200/jop.2011.000450] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
58 Wu C, Shi H, Lu M, Xu Y, Chen X. A case of hepatitis B reactivation in an anti-HBs positive, anti-HBc positive non-Hodgkin’s lymphoma patient. Virol Sin. 2013;28:49-52. [PMID: 23385354 DOI: 10.1007/s12250-013-3285-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
59 Chen Z, Engle RE, Shen CH, Zhao H, Schuck PW, Danoff EJ, Nguyen H, Nishimura N, Bock KW, Moore IN, Kwong PD, Purcell RH, Govindarajan S, Farci P. Distinct disease features in chimpanzees infected with a precore HBV mutant associated with acute liver failure in humans. PLoS Pathog 2020;16:e1008793. [PMID: 32866189 DOI: 10.1371/journal.ppat.1008793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Yang SH, Hsu C, Cheng AL, Kuo SH. Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World J Hematol 2014; 3(2): 29-43 [DOI: 10.5315/wjh.v3.i2.29] [Reference Citation Analysis]
61 Yamada T, Nannya Y, Suetsugu A, Shimizu S, Sugihara J, Shimizu M, Seishima M, Tsurumi H. Late Reactivation of Hepatitis B Virus after Chemotherapies for Hematological Malignancies: A Case Report and Review of the Literature. Intern Med. 2017;56:115-118. [PMID: 28049989 DOI: 10.2169/internalmedicine.56.7468] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
62 Hatano M, Mimura T, Shimada A, Noda M, Katayama S. Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency. Endocrinol Diabetes Metab 2019;2:e00071. [PMID: 31294085 DOI: 10.1002/edm2.71] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
63 Visram A, Feld JJ. Defining and grading HBV reactivation: Defining and Grading HBV Reactivation. Clinical Liver Disease. 2015;5:35-38. [PMID: 31040945 DOI: 10.1002/cld.426] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
64 Ciccullo A, Ponziani FR, Maiolo E, Pallavicini F, Pompili M. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report. Infection 2019;47:313-6. [PMID: 30368733 DOI: 10.1007/s15010-018-1242-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575-582. [PMID: 27076347 DOI: 10.1007/s15010-016-0891-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
66 Yuan BH, Li RH, Yuan WP, Xiang BD, Zheng MH, Yang T, Zhong JH, Li LQ. Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. Oncotarget 2017;8:51810-6. [PMID: 28881690 DOI: 10.18632/oncotarget.15395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Atteya A, Ahmad A, Daghstani D, Mushtaq K, Yassin MA. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020;27:1073274820976594. [PMID: 33297765 DOI: 10.1177/1073274820976594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
68 Matsubara K, Takahashi Y, Hayakawa A, Tanaka F, Nakadate H, Sakai M, Maeda N, Oka T, Ishii E, Bessho F, Morimoto T, Goto H, Hashii Y, Hatakeyama N, Shirahata A, Imaizumi M. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Int J Hematol 2014;99:429-36. [PMID: 24609717 DOI: 10.1007/s12185-014-1541-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
69 Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22:219-237. [PMID: 27291888 DOI: 10.3350/cmh.2016.0024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 11.2] [Reference Citation Analysis]
70 Caroleo B, Staltari O, Gallelli L, Perticone F. Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence? BMJ Case Rep 2015;2015:bcr2015209586. [PMID: 26123461 DOI: 10.1136/bcr-2015-209586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
71 Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, Asaka M, Imamura M. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010;2010:182067. [PMID: 21188195 DOI: 10.1155/2010/182067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
72 Marzano A, Marengo A, di Fonzo M, Begini P, Ferrari A, Monarca B, Delle Fave G, Marignani M. Glucocorticoids and antivirals for HBV reactivation in onco-hematologic patients. Mediterr J Hematol Infect Dis. 2010;2:e2010035. [PMID: 21415953 DOI: 10.4084/mjhid.2010.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Lieber SR, Fried MW. Controversies in hepatitis C therapy: Reactivation of hepatitis B virus. Clin Liver Dis (Hoboken) 2017;10:87-92. [PMID: 31186893 DOI: 10.1002/cld.665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Leung C, Tsoi E, Burns G, Sievert W. An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist 2011;16:579-84. [PMID: 21464465 DOI: 10.1634/theoncologist.2010-0182] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
75 Han L, Zhou J, Zhou K, Zhu X, Zhao L, Fang B, Yin Q, Wei X, Zhou H, Li L, Xu B, Zhang J, Song Y, Gao Q. Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus. J Immunother Cancer 2020;8:e000927. [PMID: 32792360 DOI: 10.1136/jitc-2020-000927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
76 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
77 Win LL, Powis J, Shah H, Feld JJ, Wong DK. Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations. Case Reports Hepatol. 2013;2013:454897. [PMID: 25374716 DOI: 10.1155/2013/454897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
78 Matsubara T, Nishida T, Shimoda A, Shimakoshi H, Amano T, Sugimoto A, Takahashi K, Mukai K, Yamamoto M, Hayashi S, Nakajima S, Fukui K, Inada M. The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection. Oncol Lett. 2017;14:6543-6552. [PMID: 29151907 DOI: 10.3892/ol.2017.7012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
79 Nabhan C, Kay NE. The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. Clin Med Insights Oncol 2011;5:45-53. [PMID: 21499555 DOI: 10.4137/CMO.S4087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
80 Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005. [PMID: 19454492 DOI: 10.3324/haematol.2009.005819] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
81 Yuen MF. Need to improve awareness and management of hepatitis B reactivation in patients receiving immunosuppressive therapy. Hepatol Int 2016;10:102-5. [PMID: 26739134 DOI: 10.1007/s12072-015-9694-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
82 Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-19. [PMID: 24247262 DOI: 10.1038/nrgastro.2013.216] [Cited by in Crossref: 155] [Cited by in F6Publishing: 137] [Article Influence: 19.4] [Reference Citation Analysis]
83 Ho EY, Yau T, Rousseau F, Heathcote EJ, Lau GK. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. Hepatol Int 2015;9:224-30. [PMID: 25788197 DOI: 10.1007/s12072-015-9612-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
84 Chan HC, Wong VW, Wong GL, Tang W, Wu JC, Ng SC. Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. BMC Gastroenterol. 2016;16:100. [PMID: 27549153 DOI: 10.1186/s12876-016-0516-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
85 Mizuno S, Yamagishi Y, Ebinuma H, Nakamoto N, Katahira M, Sasaki A, Sakamoto M, Suzuki H, Kanai T, Hibi T. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol. 2013;6:188-192. [PMID: 23606919 DOI: 10.1007/s12328-013-0371-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
86 Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17(12): 1531-1537 [PMID: 21472116 DOI: 10.3748/wjg.v17.i12.1531] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.6] [Reference Citation Analysis]
87 Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 2017;23:581-7. [PMID: 28063964 DOI: 10.1016/j.bbmt.2017.01.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
88 López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis. World J Gastroenterol 2013; 19(9): 1342-1348 [PMID: 23538480 DOI: 10.3748/wjg.v19.i9.1342] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
89 Lau KCK, Burak KW, Coffin CS. Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms 2020;8:E1470. [PMID: 32987867 DOI: 10.3390/microorganisms8101470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 37.0] [Reference Citation Analysis]
91 Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 2021;15:1031-48. [PMID: 34427860 DOI: 10.1007/s12072-021-10239-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
92 Shen Y, Hsu C, Cheng A. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010;45:794-807. [DOI: 10.1007/s00535-010-0270-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
93 Su YC, Lin PC, Yu HC, Wu CC. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74:1111-1119. [PMID: 29845351 DOI: 10.1007/s00228-018-2487-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
94 Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, Teshima T. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015; 7(21): 2344-2351 [PMID: 26413224 DOI: 10.4254/wjh.v7.i21.2344] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
95 Huang YW, Chung RT. Management of hepatitis B reactivation in patients receiving cancer chemotherapy. Therap Adv Gastroenterol. 2012;5:359-370. [PMID: 22973419 DOI: 10.1177/1756283X12450245] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
96 Chen XQ, Peng JW, Lin GN, Li M, Xia ZJ. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol. 2012;29:1237-1241. [PMID: 21556931 DOI: 10.1007/s12032-011-9974-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
97 Gutierrez C, McEvoy C, Munshi L, Stephens RS, Detsky ME, Nates JL, Pastores SM. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. Crit Care Med 2020;48:10-21. [PMID: 31725440 DOI: 10.1097/CCM.0000000000004087] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
98 Kim IK, Kim BG, Kim W, Kim D, Kim YJ, Yoon JH, Lee HS. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother 2012;56:5511-9. [PMID: 22890764 DOI: 10.1128/AAC.00821-12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
99 Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, Gallina S, Cox MC, Delle Fave G. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012; 4(3): 37-45 [PMID: 22468182 DOI: 10.4251/wjgo.v4.i3.37] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
100 Smith PJ, Suri D. Adrenalectomy to treat reactivated chronic hepatitis B infection in a patient with a steroid-secreting adrenal tumour. BMJ Case Rep 2011;2011:bcr1120103508. [PMID: 22715258 DOI: 10.1136/bcr.11.2010.3508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y. Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study. World J Gastroenterol 2013; 19(6): 923-930 [PMID: 23429298 DOI: 10.3748/wjg.v19.i6.923] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
102 Méndez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011;31:330-9. [PMID: 20738779 DOI: 10.1111/j.1478-3231.2010.02332.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
103 Villadolid J, Laplant KD, Markham MJ, Nelson DR, George TJ. Hepatitis B reactivation and rituximab in the oncology practice. Oncologist. 2010;15:1113-1121. [PMID: 20930099 DOI: 10.1634/theoncologist.2010-0106] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
104 Shoji T, Kanamori M, Inoue J, Saito R, Osada Y, Shimoda Y, Chonan M, Uenohara H, Masamune A, Tominaga T. Hepatitis B virus reactivation during temozolomide administration for malignant glioma. Int J Clin Oncol 2021;26:305-15. [PMID: 33118116 DOI: 10.1007/s10147-020-01814-7] [Reference Citation Analysis]
105 Day FL, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 2011;7:141-7. [PMID: 21886492 DOI: 10.1200/JOP.2010.000133] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 4.9] [Reference Citation Analysis]
106 Ataca Atilla P, Yalçıner M, Atilla E, İdilman R, Beksaç M. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib. Turk J Haematol 2019;36:266-73. [PMID: 31368290 DOI: 10.4274/tjh.galenos.2019.2019.0103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Wang YH, Fan L, Wang L, Zhang R, Xu J, Fang C, Li JY, Xu W. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy. Support Care Cancer. 2013;21:1265-1271. [PMID: 23151650 DOI: 10.1007/s00520-012-1656-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
108 Smalls DJ, Kiger RE, Norris LB, Bennett CL, Love BL. Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. Pharmacotherapy 2019;39:1190-203. [PMID: 31596963 DOI: 10.1002/phar.2340] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
109 Al-Mansour MM, Alghamdi SA, Alsubaie MA, Alesa AA, Khan MA. Negative effect of hepatitis in overall and progression-free survival among patients with diffuse large B-cell lymphoma. Infect Agent Cancer 2018;13:18. [PMID: 29977329 DOI: 10.1186/s13027-018-0190-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
110 Lin YC, Chen YJ, Lee SW, Lee TY, Chen YH, Huang WN, Yang SS, Chen YM. Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy. J Clin Med 2021;10:3296. [PMID: 34362079 DOI: 10.3390/jcm10153296] [Reference Citation Analysis]
111 Kuo MH, Tseng CW, Lee CH, Tung CH, Tseng KC, Lai NS. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis. Sci Rep 2020;10:2456. [PMID: 32051458 DOI: 10.1038/s41598-020-59406-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
112 Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol 2013;35:39-52. [PMID: 22829332 DOI: 10.1007/s00281-012-0327-7] [Cited by in Crossref: 131] [Cited by in F6Publishing: 123] [Article Influence: 14.6] [Reference Citation Analysis]
113 Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22:346-352. [PMID: 25220947 DOI: 10.1111/jvh.12305] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
114 Hsiao LT, Wang HY, Yang CF, Chiou TJ, Gau JP, Yu YB, Liu HL, Chang WC, Chen PM, Tzeng CH, Chan YJ, Yang MH, Liu JH, Huang YH. Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients. Medicine (Baltimore) 2016;95:e3064. [PMID: 26986131 DOI: 10.1097/MD.0000000000003064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
115 Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13-23. [PMID: 19544079 DOI: 10.1007/s12185-009-0359-5] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 10.2] [Reference Citation Analysis]
116 Sato A, Ishii T, Sano F, Yamada T, Takahashi H, Matsumoto N. Severe de novo Hepatitis B Recovered from Late-Onset Liver Insufficiency with Prolonged Ascites and Hypoalbuminemia due to Hepatitis B Virus Genotype Bj with Precore Mutation. Case Rep Gastroenterol 2016;10:553-9. [PMID: 27920641 DOI: 10.1159/000450543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
117 Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol. 2015;33:2212-2220. [PMID: 25964247 DOI: 10.1200/jco.2015.61.3745] [Cited by in Crossref: 106] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
118 Smith TE, Kister I. Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Curr Neurol Neurosci Rep 2021;21:36. [PMID: 34009478 DOI: 10.1007/s11910-021-01117-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z, Liu X, Deng Q, Li L. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection. Hematol Oncol 2021;39:75-86. [PMID: 32949412 DOI: 10.1002/hon.2807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
120 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 12.1] [Reference Citation Analysis]
121 Khan ZH, Ilyas K, Ghazanfar H, Khan HH, Hussain Q, Hammad S, Munir A, Asim R. Fatal Fulminant Hepatitis from Rituximab-induced Hepatitis B Reactivation in a Patient with Follicular Lymphoma: A Case Report and a Brief Review of Literature. Cureus. 2018;10:e2257. [PMID: 29725560 DOI: 10.7759/cureus.2257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
122 Wu C, Shi H, Wang Y, Lu M, Xu Y, Chen X. A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy. Virol Sin. 2012;27:369-372. [PMID: 23180290 DOI: 10.1007/s12250-012-3284-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
123 Yi HZ, Chen JJ, Cen H, Yan W, Tan XH. Association between infection of hepatitis B virus and onset risk of B-cell non-Hodgkin's lymphoma: a systematic review and a meta-analysis. Med Oncol 2014;31:84. [PMID: 24972912 DOI: 10.1007/s12032-014-0084-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
124 Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, Bosse E, Iqbal J, Hussain MM, Balschun K. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med. 2012;18:1060-1068. [PMID: 22706385 DOI: 10.1038/nm.2811] [Cited by in Crossref: 162] [Cited by in F6Publishing: 155] [Article Influence: 18.0] [Reference Citation Analysis]
125 Ferreira R, Carvalheiro J, Torres J, Fernandes A, Giestas S, Mendes S, Agostinho C, Campos MJ. Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: a case report and literature review. Saudi J Gastroenterol. 2012;18:277-281. [PMID: 22824772 DOI: 10.4103/1319-3767.98436] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
126 Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010;11:827-834. [PMID: 20688564 DOI: 10.1016/s1470-2045(10)70167-4] [Cited by in Crossref: 129] [Cited by in F6Publishing: 68] [Article Influence: 11.7] [Reference Citation Analysis]
127 Shinkai N, Matsuura K, Sugauchi F, Watanabe T, Murakami S, Iio E, Ogawa S, Nojiri S, Joh T, Tanaka Y. Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance. J Clin Microbiol. 2013;51:3484-3491. [PMID: 23946517 DOI: 10.1128/jcm.00726-13] [Cited by in Crossref: 43] [Cited by in F6Publishing: 11] [Article Influence: 5.4] [Reference Citation Analysis]
128 Xu X, Shang Q, Chen X, Nie W, Zou Z, Huang A, Meng M, Jin L, Xu R, Zhang JY. Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients. Cell Mol Immunol. 2015;12:309-316. [PMID: 25849120 DOI: 10.1038/cmi.2015.25] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
129 Dyson JK, Jopson L, Ng S, Lowery M, Harwood J, Waugh S, Valappil M, McPherson S. Improving testing for hepatitis B before treatment with rituximab. Eur J Gastroenterol Hepatol 2016;28:1172-8. [PMID: 27388147 DOI: 10.1097/MEG.0000000000000689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
130 Yang HC, Kao JH. Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microbes Infect 2014;3:e64. [PMID: 26038757 DOI: 10.1038/emi.2014.64] [Cited by in Crossref: 66] [Cited by in F6Publishing: 76] [Article Influence: 9.4] [Reference Citation Analysis]
131 Cao X, Wang Y, Li P, Huang W, Lu X, Lu H. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021;11:685706. [PMID: 34277431 DOI: 10.3389/fonc.2021.685706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Koo YX, Tan DS, Tan IB, Quek R, Tao M, Lim ST. “Anti-HBc alone” in human immunodeficiency virus-positive and immuno-suppressed lymphoma patients. World J Gastroenterol 2009; 15(30): 3834-3835 [PMID: 19673031 DOI: 10.3748/wjg.15.3834] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
133 Yazici O, Şendur MAN, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol 2014; 20(22): 6716-6724 [PMID: 24944464 DOI: 10.3748/wjg.v20.i22.6716] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
134 Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol 2013; 5(11): 612-620 [PMID: 24303089 DOI: 10.4254/wjh.v5.i11.612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
135 Chen KL, Chen J, Rao HL, Guo Y, Huang HQ, Zhang L, Shao JY, Lin TY, Jiang WQ, Zou DH, Hu LY, Wirian ML, Cai QQ. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chin J Cancer 2015;34:225-34. [PMID: 26058465 DOI: 10.1186/s40880-015-0015-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
136 Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013;13:534. [PMID: 24209764 DOI: 10.1186/1471-2407-13-534] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
137 Shaheen N, Mussai F. Enteroviral Encephalitis in a Child With CNS Relapse of Burkitt Leukemia Treated With Rituximab. J Pediatr Hematol Oncol 2019;41:e27-9. [PMID: 29315142 DOI: 10.1097/MPH.0000000000001077] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
138 Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 2015;94:1441-50. [PMID: 26193852 DOI: 10.1007/s00277-015-2447-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
139 Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol 2019; 25(26): 3299-3312 [PMID: 31341357 DOI: 10.3748/wjg.v25.i26.3299] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
140 Croagh CM, Lubel JS. Natural history of chronic hepatitis B: Phases in a complex relationship. World J Gastroenterol 2014; 20(30): 10395-10404 [PMID: 25132755 DOI: 10.3748/wjg.v20.i30.10395] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
141 Tsukune Y, Sasaki M, Komatsu N. Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma. Cancers (Basel) 2019;11:E1819. [PMID: 31752356 DOI: 10.3390/cancers11111819] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
142 Jun CH, Kim BS, Oak CY, Lee DH, Cho E, Cho SB, Choi SK, Park CH, Joo YE, Lee JJ, Kim HJ. HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea. Hepatol Int 2017;11:87-95. [PMID: 27351765 DOI: 10.1007/s12072-016-9747-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
143 Hwang JP, Suarez-Almazor ME, Torres HA, Palla SL, Huang DS, Fisch MJ, Lok AS. Hepatitis C virus screening in patients with cancer receiving chemotherapy. J Oncol Pract. 2014;10:e167-e174. [PMID: 24594679 DOI: 10.1200/jop.2013.001215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
144 Shiba S, Kondo S, Ueno H, Morizane C, Ikeda M, Okusaka T. Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma. Case Rep Oncol 2012;5:515-9. [PMID: 23139664 DOI: 10.1159/000342913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
145 Kelling M, Sokol L, Dalia S. Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma. Cancer Control 2018;25:1073274818767879. [PMID: 29606020 DOI: 10.1177/1073274818767879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Schmajuk G, Tonner C, Trupin L, Li J, Sarkar U, Ludwig D, Shiboski S, Sirota M, Dudley RA, Murray S, Yazdany J. Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab. Medicine (Baltimore) 2017;96:e6528. [PMID: 28353614 DOI: 10.1097/MD.0000000000006528] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
147 Ehrenstein B. [Interpretation of tuberculosis and hepatitis screening before immunosuppressive treatment]. Z Rheumatol 2018;77:493-507. [PMID: 29947949 DOI: 10.1007/s00393-018-0488-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Zhang JW, Zhang XZ, Sun YL, Long B, Wang XZ, Li XD. Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation. BMC Infect Dis 2019;19:57. [PMID: 30651070 DOI: 10.1186/s12879-019-3690-3] [Reference Citation Analysis]
149 Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012;20:2999-3008. [PMID: 22933131 DOI: 10.1007/s00520-012-1576-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
150 Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011;46:9-16. [PMID: 20924616 DOI: 10.1007/s00535-010-0331-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
151 Li Y, Yin S, Issa R, Tong X, Wang G, Xia J, Huang R, Chen G, Weng D, Chen C, Wu C, Chen Y. B Cell-mediated Humoral Immunity in Chronic Hepatitis B Infection. J Clin Transl Hepatol 2021;9:592-7. [PMID: 34447690 DOI: 10.14218/JCTH.2021.00051] [Reference Citation Analysis]
152 Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133:137-146. [PMID: 30341058 DOI: 10.1182/blood-2018-04-848044] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 15.7] [Reference Citation Analysis]
153 Liang JH, Gao R, Dai JC, Gale RP, Li W, Fan L, Hu ZB, Xu W, Li JY. The prognostic role of HBV infection in chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2018;144:1309-15. [PMID: 29761374 DOI: 10.1007/s00432-018-2663-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
154 Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol 2016; 22(39): 8720-8734 [PMID: 27818588 DOI: 10.3748/wjg.v22.i39.8720] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 62] [Article Influence: 14.4] [Reference Citation Analysis]
155 Çeneli &, Özkurt ZN, Acar K, Rota S, Akı ŞZ, Yeğin ZA, Yağcı M, Özenirler S, Sucak GT. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients. World J Gastroenterol 2010; 16(14): 1765-1771 [PMID: 20380010 DOI: 10.3748/wjg.v16.i14.1765] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
156 Fuentes A, Mardones C, Burgos PI. Understanding the Cryoglobulinemias. Curr Rheumatol Rep. 2019;21:60. [PMID: 31741077 DOI: 10.1007/s11926-019-0859-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
157 Oh MJ, Lee HJ. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. Clin Mol Hepatol. 2013;19:51-59. [PMID: 23593610 DOI: 10.3350/cmh.2013.19.1.51] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
158 Zhang MY, Zhu GQ, Shi KQ, Zheng JN, Cheng Z, Zou ZL, Huang HH, Chen FY, Zheng MH. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016;7:30642-30658. [PMID: 27121321 DOI: 10.18632/oncotarget.8907] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
159 Law MF, Ho R, Cheung CK, Tam LH, Ma K, So KC, Ip B, So J, Lai J, Ng J, Tam TH. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol 2016; 22(28): 6484-6500 [PMID: 27605883 DOI: 10.3748/wjg.v22.i28.6484] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
160 Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol 2014; 6(12): 860-869 [PMID: 25544873 DOI: 10.4254/wjh.v6.i12.860] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
161 Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, Saitis A, Boura P, Dalekos GN. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. World J Hepatol 2013; 5(7): 387-392 [PMID: 23898372 DOI: 10.4254/wjh.v5.i7.387] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
162 Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol 2015; 7(6): 825-830 [PMID: 25937860 DOI: 10.4254/wjh.v7.i6.825] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
163 Wu T, Kwok RM, Tran TT. Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues. Am J Gastroenterol 2017;112:1780-8. [PMID: 29087395 DOI: 10.1038/ajg.2017.397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
164 Herr MM, Schonfeld SJ, Dores GM, Engels EA, Tucker MA, Curtis RE, Morton LM. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes. Blood Adv 2019;3:1961-9. [PMID: 31262739 DOI: 10.1182/bloodadvances.2019030924] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
165 Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih YT, Chavez-MacGregor M, Duan Z, Giordano SH, Hershman DL, Fisch MJ, Cantor SB. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform 2019;3:1-12. [PMID: 30892921 DOI: 10.1200/CCI.18.00097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
166 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
167 Zannella A, Marignani M, Begini P. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. Viruses 2019;11:E858. [PMID: 31540124 DOI: 10.3390/v11090858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
168 Reynolds JA, Manch RA, Gish RG. Medical interventions associated with HBV reactivation: Common and less common. Clinical Liver Disease. 2015;5:32-34. [PMID: 31040944 DOI: 10.1002/cld.413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
169 Totani H, Kusumoto S, Ishida T, Masuda A, Yoshida T, Ito A, Ri M, Komatsu H, Murakami S, Mizokami M. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy. Int J Hematol. 2015;101:398-404. [PMID: 25633779 DOI: 10.1007/s12185-015-1750-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
170 Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Gómez Rubio M, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2017;12:e0184550. [PMID: 28898281 DOI: 10.1371/journal.pone.0184550] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
171 Gu HR, Shin DY, Choi HS, Moon CH, Park SC, Kang HJ. HBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT. Blood Res. 2015;50:51-53. [PMID: 25830131 DOI: 10.5045/br.2015.50.1.51] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
172 Lee J, Park JY, Kim DG, Lee JY, Kim BS, Kim MS, Il Kim S, Kim YS, Huh KH. Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. Sci Rep 2018;8. [DOI: 10.1038/s41598-018-34111-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
173 Chinese Society of Lymphoma, Chinese Anti-cancer Association., Chinese Society of Hematology, Chinese Medical Association. [The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:441-6. [PMID: 34384148 DOI: 10.3760/cma.j.issn.0253-2727.2021.06.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Tsai YF, Hsu CM, Hsiao HH. Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment. J Pers Med 2021;11:267. [PMID: 33918206 DOI: 10.3390/jpm11040267] [Reference Citation Analysis]
175 Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol 2015; 21(36): 10274-10289 [PMID: 26420955 DOI: 10.3748/wjg.v21.i36.10274] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]